Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Executives, Big Pharma, NCI Among Board of New Personalized Medicine Nonprofit

NEW YORK, Oct. 21 (GenomeWeb News) - Executives from Affymetrix, Genomas, and Genomic Health are part of more than 20 companies, academic centers, and government agencies that have formed the Personalized Medicine Coalition, a nonprofit group, the association said today.


Edward Abrahams, former executive director of the Pennsylvania Biotechnology Association, is the PMC executive director, according to a statement.


The PMC board comprises of executives from Abbott Laboratories, Affymetrix, Amgen, AstraZeneca Pharmaceuticals, the Biotechnology Industry Organization, Genentech, Genomas, Genomic Health, Roche, IBM, Pfizer, and the Pharmaceutical Research and Manufacturers of America. The US National Cancer Institute and the US National Human Genome Research Institute are "also active" as ex-officio members, the statement added.


The PMC will focus on topics including: the implications of privacy laws and intellectual property laws in personalized medicine; global developments in biorepositories; and "the value proposition" of emerging drugs and molecular-based tests, the organization said.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.